MDxHealth (NASDAQ:MDXH – Get Free Report) and MannKind (NASDAQ:MNKD – Get Free Report) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their institutional ownership, earnings, risk, profitability, dividends, analyst recommendations and valuation.
Profitability
This table compares MDxHealth and MannKind’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| MDxHealth | -33.46% | N/A | -24.25% |
| MannKind | -11.08% | -11.21% | -6.31% |
Analyst Recommendations
This is a summary of current ratings and recommmendations for MDxHealth and MannKind, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| MDxHealth | 1 | 1 | 3 | 0 | 2.40 |
| MannKind | 2 | 1 | 7 | 0 | 2.50 |
Valuation & Earnings
This table compares MDxHealth and MannKind”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| MDxHealth | $107.88 million | 0.29 | -$33.52 million | ($0.72) | -0.88 |
| MannKind | $393.63 million | 2.89 | $5.86 million | ($0.13) | -27.23 |
MannKind has higher revenue and earnings than MDxHealth. MannKind is trading at a lower price-to-earnings ratio than MDxHealth, indicating that it is currently the more affordable of the two stocks.
Institutional and Insider Ownership
49.5% of MannKind shares are owned by institutional investors. 1.7% of MDxHealth shares are owned by insiders. Comparatively, 2.6% of MannKind shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Volatility & Risk
MDxHealth has a beta of 1.57, suggesting that its stock price is 57% more volatile than the S&P 500. Comparatively, MannKind has a beta of 1.1, suggesting that its stock price is 10% more volatile than the S&P 500.
Summary
MannKind beats MDxHealth on 10 of the 14 factors compared between the two stocks.
About MDxHealth
MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, Europe, and internationally. Its testing solutions includes Select mdx, a non-invasive urine test for prostate cancer that measures the expression of two mRNA cancer-related biomarkers; Confirm mdx for prostate cancer tissue test that validates epigenetic test that guides the detection of occult prostate cancer on a patient's previously biopsied negative tissue; and Resolved mdx for urinary tract infection that identifies personalized effective antibiotic options against the patient's infection. The company offers genomic prostate score which provides personalized genomic insights to both physicians and patients navigating the complexities of prostate cancer diagnosis and treatment. It sells its products through urology sales force, consisting of direct sales representatives, strategic account managers, and regional sales managers. The company was formerly known as OncoMethylome Sciences SA and changed its name to MDxHealth SA in October 2010. MDxHealth SA was incorporated in 2003 and is headquartered in Herstal, Belgium.
About MannKind
MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. The company's product pipeline also includes Tyvaso DPI (Treprostinil), an inhalation powder for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; MNKD-101, a nebulized formulation of clofazimine, for the treatment of severe chronic and recurrent pulmonary infections, including nontuberculous mycobacterial lung disease; MNKD-201, a dry-powder formulation of nintedanib, for the treatment of idiopathic pulmonary fibrosis (IPF). In addition, it has collaboration and license agreement with United Therapeutics Corporation for development, regulatory, and commercial activities of Tyvaso DPI; co-promotion agreement with Vertice Pharma to promote Thyquidity; and collaboration agreement with Thirona to evaluate the therapeutic for the treatment of pulmonary fibrosis. Further, the company has supply and distribution agreement with Biomm S.A. for the commercialization of Afrezza in Brazil; and license and distribution agreement with Cipla Ltd. for the marketing and distribution of Afrezza in India. MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut.
Receive News & Ratings for MDxHealth Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MDxHealth and related companies with MarketBeat.com's FREE daily email newsletter.
-logo-1200x675.png){kind=logo}
